CY1110165T1 - NEW FORMS OF MAGNESIUM SALT [R- (R *, R *)] - 2- (4-Fluorophenyl) -B, B-Dihydroxy-5- (1-Methylethyl) -3-5 phenyl-4 - [(FINYL) Carbonyl] -1H-pyrrolo-1-heptanoic acid - Google Patents

NEW FORMS OF MAGNESIUM SALT [R- (R *, R *)] - 2- (4-Fluorophenyl) -B, B-Dihydroxy-5- (1-Methylethyl) -3-5 phenyl-4 - [(FINYL) Carbonyl] -1H-pyrrolo-1-heptanoic acid

Info

Publication number
CY1110165T1
CY1110165T1 CY20101100606T CY101100606T CY1110165T1 CY 1110165 T1 CY1110165 T1 CY 1110165T1 CY 20101100606 T CY20101100606 T CY 20101100606T CY 101100606 T CY101100606 T CY 101100606T CY 1110165 T1 CY1110165 T1 CY 1110165T1
Authority
CY
Cyprus
Prior art keywords
magnesium salt
new forms
finyl
pyrrolo
methylethyl
Prior art date
Application number
CY20101100606T
Other languages
Greek (el)
Inventor
Jason Albert Leonard
Jonathan Mark Miller
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06809231A external-priority patent/EP1957452B1/en
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of CY1110165T1 publication Critical patent/CY1110165T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Περιγράφονται νέες μορφές άλατος μαγνησίου ατορβαστατίνης που ορίζονται μορφή Α, Μορφή Β, Μορφή C, Μορφή D, Μορφή Ε και Μορφή F, φαρμακευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις, μέθοδοι για την παρασκευή αυτών και μέθοδοι χρήσης των ενώσεων για θεραπεία υπερλιπιδαιμίας, υπερχοληστερολαιμίας, οστεοπόρωσης, καλοήθους προστατικής υπερπλασίας (ΒΡΗ) και ασθένειας Alzheimer.New forms of atorvastatin magnesium salt are defined as Form A, Form B, Form C, Form D, Form E and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods of use for the treatment of hyperlipidemia, hyperlipidemia , benign prostatic hyperplasia (BPH) and Alzheimer's disease.

CY20101100606T 2005-11-21 2010-07-01 NEW FORMS OF MAGNESIUM SALT [R- (R *, R *)] - 2- (4-Fluorophenyl) -B, B-Dihydroxy-5- (1-Methylethyl) -3-5 phenyl-4 - [(FINYL) Carbonyl] -1H-pyrrolo-1-heptanoic acid CY1110165T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73844705P 2005-11-21 2005-11-21
EP06809231A EP1957452B1 (en) 2005-11-21 2006-11-09 Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium

Publications (1)

Publication Number Publication Date
CY1110165T1 true CY1110165T1 (en) 2015-01-14

Family

ID=42664731

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100606T CY1110165T1 (en) 2005-11-21 2010-07-01 NEW FORMS OF MAGNESIUM SALT [R- (R *, R *)] - 2- (4-Fluorophenyl) -B, B-Dihydroxy-5- (1-Methylethyl) -3-5 phenyl-4 - [(FINYL) Carbonyl] -1H-pyrrolo-1-heptanoic acid

Country Status (1)

Country Link
CY (1) CY1110165T1 (en)

Similar Documents

Publication Publication Date Title
WO2005105738A3 (en) Salt forms of atorvastatin
GEP20053546B (en) Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin)
CL2004000985A1 (en) COMPOUNDS DERIVED FROM PHENYLQUINOLINS; PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS; AND USE TO TREAT OSTEOPOROSIS, PAGET DISEASE, VASCULAR DANO, OSTEOARTRITIS, OSEO CANCER, OVARIC CANCER, PROSTATIC CANCER, HYPERCHOLESTEROLEMIA, ATEROSC
NO20035526D0 (en) Compounds for the treatment of metabolic disorders
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
BR0116785A (en) Process for synthesizing Form V of atorvastatin and phenylboronates as intermediate compounds
EA200602196A1 (en) DERIVATIVES OF PYRAZOL, COMPOSITIONS CONTAINING THESE CONNECTIONS AND METHODS OF APPLICATION
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
MXPA05011536A (en) Phenyl substituted carboxylic acids.
EP1841426A4 (en) Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
BRPI0518300A2 (en) 7- (2h-pyrazol-3-yl) -3,5-dihydroxyheptanoic acid derivatives as hmg co-reductase inhibitors for the treatment of lipidemia
NO20084362L (en) Diphenyllazetidinone derivatives containing cholesterol absorption inhibitor activity
WO2004027075A3 (en) Chemoenzymatic methods for the synthesis of statins and stain intermediates
EA200702674A1 (en) METHOD FOR TREATING ATHEROSCLEROSIS, DISLIPIDEMIA AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS
CY1109045T1 (en) RETINOID FOR INFECTION TREATMENT
DK1443967T3 (en) Combination of cyclooxygenase-2 inhibitor / histone deacetylase inhibitor
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
PE20050523A1 (en) PYRAZOLES AS TUMOR NECROSIS FACTOR INHIDORS
WO2007058862A3 (en) Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
DE602005007912D1 (en) DERIVATIVES OF 1-PHENYLALKANCARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES